Industry News

Magellan Health, Inc. today announced that it will release third quarter 2016 earnings results on Wednesday, November 9, 2016. Management will discuss the company's financial results, as well as its business strategy and outlook, on a conference call to be held the same day from 9:00 a.m. to 10:00 a.m. Eastern. The press release detailing the company's third quarter 2016 earnings results will be issued at approximately 6:30 a.m. Eastern, and will be..."/>
Magellan Health Announces Third Quarter 2016 Earnings Conference Call
Retractable Technologies, Inc. announced today that its Board of Directors has declared dividends to holders of its Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $12,312.50 and $42,800.00, respectively. The dividend amount is $0.125 per share for Series I Class B shareholders and $0.25 per share for Series II Class B shareholders. Dividends have accrued at 10% per annum and cover amounts in arrears from and including July..."/>
Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Preferred Stock Shareholders
Cigna to produce letters they have sent accusing each other of breaching an agreement in which Anthem would purchase Cigna. The federal antitrust regulators discovered the letters because Cigna's lawyer told an official on Aug. 16 that both its in-house attorney and Anthem's have "exchanged letters accusing each other of breaching the merger agreement." The next day, the DOJ, served Anthem and Cigna..."/>
Anthem, Cigna Accuse Each Other Of Breaching Merger Agreement [The Hartford Courant]
UnitedHealth Group will release its financial results for the third quarter of 2016 on Tuesday, October 18, 2016, before the market opens, and will host a teleconference at 8:45 a.m. ET to discuss the results with analysts and investors. This call will be webcast on the Investors page of the company's web site. The replay will be available on the web site or by dialing 1-800-283-4799 through November 1."/>
UnitedHealth Group Schedules Third Quarter Earnings Release and Conference Call for October 18, 2016
Genmab A/S. COPENHAGEN, Denmark, Sept. 22, 2016-- Genmab A/S announces under reference to Section 29 of the Danish Securities Trading Act that Baillie Gifford& Co has informed us that, as of September 22, 2016, Baillie Gifford& Co has increased their indirect ownership in Genmab A/S to 3,021,069 shares, which amounts to 5.02% of the share capital and voting rights in Genmab A/S.. About Genmab Genmab is a publicly traded, international biotechnology..."/>
Major Shareholder Announcement
SolarCity solar panel factory, IBM's data analytics center in Buffalo and the Albany Molecular Research Inc. drug development venture on the Buffalo Niagara Medical Campus, already have opened or are in advanced stages."/>
What the corruption charges will mean for the Buffalo Billion [The Buffalo News, N.Y.]
Pfizer Inc. today declared a 30- cent fourth-quarter 2016 dividend on the company’ s common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016. The fourth-quarter 2016 cash dividend will be the 312 th consecutive quarterly dividend paid by Pfizer. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives."/>
Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend
Misonix, Inc. concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired shares between November 5, 2015 and September 14, 2016 are encouraged to contact the Firm before the November 18, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here."/>
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Misonix, Inc. and Encourages Investors with Losses to Contact the Firm
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that it has signed an Investigator-Initiated Clinical Trial Agreement with the University of California, San Diego, School of Medicine. The proposed study is a Phase I/IIa trial to assess safety, tolerability, efficacy, and pharmacokinetics of Aramchol..."/>
Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreement to Assess Aramchol™ Effects Juvenile Population
Apollo Hospitals Enterprise Ltd., Chennai, Tamil Nadu, India. Includes the following: Apollo Hospitals International Ltd., Ahmedabad Apollo Hospitals, Chennai Apollo..."/>
AAHRPP Accredits Three More Research Organizations: One in India, two in U.S.
Agilent Technologies Inc. today announced the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality FISH into their IHC workflow."/>
Agilent Technologies Launches New Panel for Fast FISH Testing on Dako Omnis in Lung Cancer
Baxter International Foundation and the global humanitarian organization Direct Relief. This Smart News Release features multimedia. View the full release here:"/>
The Baxter International Foundation and Direct Relief Launch a Mobile Health Initiative Bringing Life-Saving Medical Treatment and Education to Hundreds of Thousands in Mexico City
Magellan Health, Inc. today released its Medicaid Trend Report, developed through in-depth data analysis and supported by Magellan’ s broad national experience managing the fee-for-service Medicaid pharmacy programs for 25 states and Washington, D.C. The report, the first of its kind, examines clinically appropriate drug use and cost-savings opportunities for Medicaid FFS programs..."/>
Magellan Rx Management's Medicaid Trend Report Highlights Strategies for States to Improve Care, Lower Costs
Immune Therapeutics, Inc., a clinical-stage pharmaceutical company focused on the commercialization and development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer, today announces the appointment of two new members to its Medical and Clinical Advisory Board comprised of: Joseph M. Chalil, MD and Mak Jawadekar, Ph.D., join Clifford A. Selsky,..."/>
Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board
LivaNova PLC, a market-leading medical technology company, announced today the launch of PLATINIUM, its next-generation range of implantable cardiac defibrillators and cardiac resynchronization therapy devices. PLATINIUM models offer unmatched longevity 1 thanks to LivaNova's..."/>
LivaNova Launches Next Generation ICD and CRT-D Devices in the United States
LivaNova PLC, a market-leading medical technology company, announced today the launch of PLATINIUM, its next-generation range of implantable cardiac defibrillators and cardiac resynchronization therapy devices. PLATINIUM models offer unmatched longevity 1 thanks to LivaNova’ s breakthrough..."/>
LivaNova Launches Next Generation ICD and CRT-D Devices in the United States
Canon U.S.A., Inc., a leader in digital imaging solutions, today announced that it has made an equity investment in T2 Biosystems, Inc., a company developing innovative diagnostic products to improve patient health. Through this investment, Canon U.S.A. has purchased approximately 40 million dollars of the company's stock at the closing market price of $6.56 in a private placement, resulting in Canon's ownership of approximately 19.9..."/>
Canon U.S.A. Announces Equity Investment in T2 Biosystems, Inc.
Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced it will present at the Leerink Partners Immuno-Oncology Roundtable on Thursday, September 29, 2016 at 8:30 a.m. Eastern Time in New York, NY. The presentation will be webcast live and..."/>
Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable
Pacific Biosciences of California, Inc.,, and Dovetail Genomics™ LLC today announced that Dovetail has added PacBio ® SMRT ® sequencing and de novo assembly options to its menu of genome assembly services. The companies also announced their signing of a co-marketing agreement under which the new service offerings will be jointly promoted. "We are impressed by Dovetail's continued commitment to deliver the most..."/>
Dovetail Genomics Adds PacBio SMRT Sequencing and Assembly to Its Services Menu
Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the completion of its previously announced private placement of an aggregate of approximately 22,500 shares of the Company's Series A Preferred Stock and five-year warrants to purchase an aggregate of approximately 32,142,857 shares of the Company's common stock for gross..."/>
Roka Bioscience, Inc. Completes Private Placement of Preferred Stock and Warrants

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology716 Articles
Consumer Discretionary622 Articles
Financials479 Articles
Industrials415 Articles
Health Care405 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at